

# FLULAVAL Tetra

inactivated influenza vaccine (2022-23)  
quadrivalent, standard dose

DIN 02420783



SUPPLIED:  
multidose vial



PREPARATION:  
ready-to-use;  
do not dilute



ADMINISTRATION:  
IM injection



APPROPRIATE  
USE:

- **5 years & older** (approved 6 months & older)
- **< 9 years old**— confirm no influenza vaccine in last 28 days



BEYOND-USE  
EXPIRY  
DATE/TIME:

- **Unpunctured:** 2°C to 8°C: use vaccine until expiry date
- **Punctured:** 2°C to 8°C: use vaccine within 28 days of first puncture



HANDLING:

- SHAKE before withdrawing each dose



APPEARANCE:

- opalescent translucent to off-white suspension, may sediment slightly
- NO particulate matter/discolouration



DOSE:

0.5 mL

Children < 9 years old who have not previously received seasonal influenza vaccine require 2 doses given at least 4 weeks apart



VIAL  
STORAGE:

- between 2°C and 8°C for no more than 28 days after first puncture
- protect from light

REFERENCES:

- Flulaval Tetra Product Monograph. GlaxoSmithKline Inc. Mississauga ON. LSN 4H1. April 20, 2022.  
Available from: [https://pdf.hres.ca/dpd\\_pm/00067351.PDF](https://pdf.hres.ca/dpd_pm/00067351.PDF)

# FLULAVAL Tetra

inactivated influenza vaccine (2022-23)  
quadrivalent, standard dose

DIN 02420783



SUPPLIED:  
multidose vial



PREPARATION:  
ready-to-use;  
do not dilute



ADMINISTRATION:  
IM injection



APPROPRIATE  
USE:

- **5 years & older** (approved 6 months & older)
- **< 9 years old**— confirm no influenza vaccine in last 28 days



BEYOND-USE  
EXPIRY  
DATE/TIME:

- **Unpunctured:** 2°C to 8°C: use vaccine until expiry date
- **Punctured:** 2°C to 8°C: use vaccine within 28 days of first puncture



HANDLING:

- SHAKE before withdrawing each dose



APPEARANCE:

- opalescent translucent to off-white suspension, may sediment slightly
- NO particulate matter/discolouration



DOSE:

0.5 mL

Children < 9 years old who have not previously received seasonal influenza vaccine require 2 doses given at least 4 weeks apart



VIAL  
STORAGE:

- between 2°C and 8°C for no more than 28 days after first puncture
- protect from light

REFERENCES:

- Flulaval Tetra Product Monograph. GlaxoSmithKline Inc. Mississauga ON. LSN 4H1. April 20, 2022.  
Available from: [https://pdf.hres.ca/dpd\\_pm/00067351.PDF](https://pdf.hres.ca/dpd_pm/00067351.PDF)